Pharma leaders agree that real-world data (RWD) is essential—but many still struggle to harness its full potential. In Real-World Data in 2025 and Beyond: Closing the Strategy Gap, Norstella surveyed 200 life sciences executives to uncover how organizations are using RWD, where they’re falling short, and what separates high-performing strategies from the rest.
The findings reveal that while 92.5% of companies report strong ROI from RWD, most face persistent barriers like data integration challenges, quality issues, and slow insights. The paper outlines how a cohesive, AI-driven RWD strategy—anchored in clear objectives, fit-for-purpose data, and clinical expertise—can turn raw data into actionable evidence that accelerates trials, strengthens market access, and improves patient outcomes.
Those who invest now in a unified, forward-looking RWD approach won’t just keep pace with the industry—they’ll lead it.